ClinicalTrials.gg
RecruitingNCT06078436PACE-SHOCKUpdated Jan 5, 2024

Pulmonary Artery Catheterization and Carvedilol Early Initiation in Cardiogenic SHOCK Due to HFrEF

An interventional study of Pulmonary artery catheter in Heart Failure With Reduced Ejection Fraction and Cardiogenic Shock, sponsored by Min-Seok Kim. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by Min-Seok Kim · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Shock, Cardiogenic with a site in Korea, Republic of — 8 open to participants now, 8 under way, none of them phase 3. Shock, Cardiogenic · Korea, Republic of.

Planned enrollment
6th of 10
160 · median 280
Started
2024
with 1 other
No phase
8 of 13
5 open now
Registered
9th of 13
by date
Lead sponsor
2 of 13
Min-Seok Kim

Among the 13 studies in Shock, Cardiogenic with a site in Korea, Republic of, this one is the 6th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2024, is one of 8 with no phase, and was the 9th registered.

Shock, Cardiogenic

297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

Browse Shock, Cardiogenic studies →

Open to participants now

8 of the 13 studies in Shock, Cardiogenic with a site in Korea, Republic of are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Shock, Cardiogenic with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study aims to compare the impact of hemodynamic monitoring using pulmonary artery catheter (PAC) on survival and inotropic agent reduction in patients with cardiogenic shock caused by heart failure with reduced ejection fraction (HFrEF). The investigators also intend to compare the difference in long-term survival rates among patients who have recovered from cardiogenic shock due to HFrEF, based on the timing of initiation of beta-blocker treatment.

Read the detailed description

Cardiogenic shock is one of the most common causes of shock patients admitted to the Cardiac Intensive Care Unit (CICU). Despite advances in treatment, the mortality rate of cardiogenic shock remains high, up to 50%, and improving survival is crucial through the use of inotropic agents, vasopressors, or mechanical circulatory support devices to improve hemodynamic parameters. Previous meta-analyses of retrospective studies have shown the usefulness of pulmonary artery catheter monitoring, especially in patients with cardiogenic shock due to heart failure. However, there is a lack of prospective studies regarding specific monitoring indicators and treatment goals. This study aims to compare the impact of hemodynamic monitoring through pulmonary artery catheter on survival and inotropic agent reduction in patients with cardiogenic shock caused by heart failure with reduced ejection fraction.

In the PAC non-monitoring group, various assessments such as physical examination, echocardiographic findings, serum lactate levels, chest x-ray, and laboratory test results are utilized. If there are signs of volume overload, diuretics or hemodialysis may be applied to achieve for volume reduction. The dosage of diuretics and the timing of hemodialysis are at the discretion of the attending physician. The target of a mean arterial pressure (MAP) is 65mmHg or higher. If the MAP falls below 65mmHg, increasing vasopressor or inotropes should be considered. If the MAP target is not achieved with medical therapy or if serum lactate levels increase by 3 mmol/L or more compared to the lowest value within 24 hours, mechanical circulatory support (MCS) is considered. The specific dosage of vasopressors/inotropes and the timing of MCS application are at the dscretion of the attending physician.

The PAC monitoring group, in addition to those used in the PAC non-monitoring group, treats patients using indicators measured by PAC. The targets include a right atrial pressure (RAP) or central venous pressure (CVP) of 8mmHg or lower and pulmonary capillary wedge pressure (PCWP) of 15mmHg or lower. Whan RAP or CVP exceeds 8mmHg, or PCWP exceeds 15mmHg, employing diuretics or hemodialysis should be considered for volume reduction. The dosage of diuretics and the timing of hemodialysis are at the discretion of the attending physician. The target of a mean arterial pressure (MAP) is 65mmHg or higher. If the MAP falls below 65mmHg, increasing vasopressor or inotropes should be considered. If the MAP target is not achieved with medical therapy or if serum lactate levels increase by 3 mmol/L or more compared to the lowest value within 24 hours, mechanical circulatory support (MCS) is considered. The specific dosage of vasopressors/inotropes and the timing of MCS application are at the dscretion of the attending physician.

Additionally, the beta-blocker Carvedilol is known to reduce mortality and readmission rates in heart failure patients based on large-scale clinical trials and is widely prescribed as a standard treatment. However, the evidence for the appropriate timing of Carvedilol initiation and objective indicators of hemodynamic stability beyond the point of discharge is currently insufficient, relying solely on the clinical judgment and experience of the treating physician. Through subgroup analysis, the investigators intend to compare the difference in long-term survival rates among patients who have recovered from cardiogenic shock due to heart failure with reduced ejection fraction, based on the timing of iniation of beta-blocker treatment. The early administration of Carvedilol is defined as initiating treatment within 24 to 48 hours after discontinuing vasopressor/inotropic agents or mechanical circulatory support in stable condition following cardiogenic shock. The conservative administration of Carvedilol is defined as initiating treatment at least 48 hours after discontinuing vasopressors/inotropic agents or mechanical circulatory support in stable condition following cardiogenic shock.

Also, lung B-line will be measure along with PAC measured hemodynamic parameters using lung ultrasound at eight regions of the thorax in patients with PAC monitoring. Number of B-line in a total and each region, positive region which is defined as having three or more number of B-line will be recorded. Acquired images will be adjudicated by two investigators who are blinded to the clinical information of the subject.

03

Conditions studied

  • Heart Failure With Reduced Ejection Fraction
  • Cardiogenic Shock

Browse trials for

Keywords

  • Cardiogenic shock
  • Heart failure with reduced ejection fraction (HFrEF)
  • Hemodynamic monitoring
  • Pulmonary artery catheter
  • Carvedilol
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults age 19 and above ( no age limit for elderly )
  • Patients with cardiogenic shock requiring intensive care monitoring in ICU
  • Patients eligible for oral medication administration
  • Patients who have provided research participation consent through a written form

Exclusion criteria

Exclusion Criteria:

  • Unwilling or unable to obtain by the participant or substitute decision maker
  • Patients with mechanical circulatory support at the time of screening
  • Patients with acute coronary syndrome
  • Patients with severe valvular heart disease requiring emergent percutaneous procedures or surgery
  • Known to beta-blockers
  • Patients with a history of bronchospasm or asthma
  • Patients with bradycardia or second or third-degree atrioventricular block
  • Patients with sick sinus syndrome, including sinoatrial block
  • Patients with untreated pheochromocytoma
  • Patients currently undergoing de-sensitization therapy
  • Patients who are currently pregnant, postpartum period within 30 days or breast-feeding
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Pulmonary artery catheter monitoring group

    Within 8 hours of random allocation, a pulmonary artery catheter will be inserted to monitor hemodynamic parameters.

    Device: Pulmonary artery catheter

  • Active comparator
    No pulmonary artery catheter monitoring group

    After random allocation, a pulmonary artery catheter will not be inserted during cardiogenic shock management.

    Device: Pulmonary artery catheter

Interventions

  • DevicePulmonary artery catheter

    Pulmonary artery catheter monitoring or not

    Also known as: Swan-Ganz catheter

06

What researchers measure

Primary outcomes

  1. 30-day all-cause mortality

    All-cause mortality

    Time frame: From date of randomization until the date of death from any cause, assessed up to 30 days

Secondary outcomes

  1. All-cause mortality

    All-cause of death

    Time frame: From date of randomization until the date of death from any cause, assessed up to 3 months

  2. Cardiovascular mortality

    Cardiovascular death

    Time frame: From date of randomization until the date of death from any cause, assessed up to 3 months

  3. Timing of discontinuation of inotropic or vasopressor agents

    Days from randomization to discontinuation of inotropes/vasopressor

    Time frame: From date of randomization until the date of discharge or assessed up to 90 days

  4. The rate of Carvedilol intake on the 3 months

    The rate of Carvedilol intake

    Time frame: 3 months from date of randomization

  5. The target-dose achievement rate of Carvedilol on the 3 months

    Target dose : 50mg/day

    Time frame: 3 months from date of randomization

  6. 3-month follow-up echocardiography parameters

    LVEF(left ventricular ejection fraction)

    Time frame: 3 months from date of randomization

  7. Complications related with pulmonary artery catheter

    Any complications related with pulmonary artery catheter

    Time frame: During hospitalization period, up to 30 days

  8. Hospitalization due to heart failure

    Unplanned hospitalization due to heart failure

    Time frame: 3 months from date of randomization

  9. The composite outcome of cardoivascular death and heart failure hospitalization

    The composite outcome of cardiovascular death and hospitalization due to heart failure

    Time frame: 3 months from date of randomization

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2024; primary completion for Sep 2027, 44 months later.

Of 48 non-industry interventional studies with no phase under Shock, Cardiogenic, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 44 months is above that.

Counting every sponsor, half of 52 studies reached it within 39 months; a quarter within 24 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2023
First posted
Oct 11, 2023
StartEst.
Jan 2024
Primary completionEst.
Sep 2027
CompletionEst.
Mar 2028
Last update
Jan 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06078436
Lead sponsor
Min-Seok Kim
Responsible party
Min-Seok Kim (Clinical Associate Professor, Asan Medical Center) — Sponsor-investigator
First posted
Oct 11, 2023
Start date
Jan 2024 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Jan 5, 2024

Study contacts

Min-Seok Kim, PhD
Contact
msk@amc.seoul.kr
82-2-3010-3948
Ah-Ram Kim, MD
Contact
ahram3256@amc.seoul.kr
82-2-3010-0111
Min-Seok Kim
study chair · Asan Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion